Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 18, 2007, Pages 3257-3264

  Hochhaus, Andreas ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

BCR ABL; chronic myelogenous leukemia; dasatinib; imatinib; Philadelphia chromosome

Indexed keywords

ANTINEOPLASTIC AGENT; DASATINIB; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; THIAZOLE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; COMPARATIVE STUDY; DRUG RESISTANCE; GENETICS; GENOTYPE; HUMAN; PHILADELPHIA 1 CHROMOSOME; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; GENOTYPE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PHILADELPHIA CHROMOSOME; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 38549167019     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.8.18.3257     Document Type: Article

References (40)

1. REDAELLI A, BELL C, CASAGRANDE J et al. : Clinical and epidemiologic burden of chronic myelogenous leukemia. Expert Rev. Anticancer Ther. (2004) 4:85-96.
2. KANTARJIAN HM, GILES F, QUINTAS-CARDAMA A, CORTES J: Important therapeutic targets in chronic myelogenous leukemia. Clin. Cancer Res. (2007) 13:1089-1097.
3. BACCARANI M, SAGLIO G, GOLDMAN J et al. : Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood (2006) 108:1809-1820.
4. HOCHHAUS A, ERBEN P, ERNST T, MUELLER MC: Resistance to targeted therapy in chronic myelogenous leukemia. Semin. Hematol. (2007) 44:15-24.
5. SHAH NP: Loss of response to imatinib: mechanisms and management. Hematol. Am. Soc. Hematol. Educ. Program (2005):183-187.
6. HOCHHAUS A, LA ROSÉE P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia (2004) 18:1321-1331.
7. RITCHIE E, NICHOLS G: Mechanisms of resistance to imatinib in CML patients: a paradigm for the advantages and pitfalls of molecularly targeted therapy. Curr. Cancer Drug Targets (2006) 6:645-657.
8. O'BRIEN SG, GUILHOT F, LARSON RA et al. : Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348:994-1004.
9. DRUKER BJ, GUILHOT F, O'BRIEN SG et al. : Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. (2006) 355:2408-2417.
10. BRANFORD S, RUDZKI Z, HARPER A et al. : Imatinib produces signifi cantly superior molecular responses compared to interferon α plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Leukemia (2003) 17:2401-2409.
11. KANTARJIAN HM, TALPAZ M, O'BRIEN S et al. : Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood (2003) 101:473-475.
12. NOVARTIS PHARMA AG BS: Imatinib (Gleevec) prescribing information. Imatinib (Gleevec) prescribing information (2007).
13. KANTARJIAN HM, GILES F, GATTERMANN N et al.: Nilotinib (formerly AMN107), a highly selective Bcr-Abl tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood ( 2007 ):[Epub ahead of print].
14. LE COUTRE P, LARSON R, KANTARJIAN H et al. : A Phase II study of nilotinib, a novel tyrosine kinase inhibitor administered to imatinib-resistant or-intolerant patients with Philadelphia-positive chronic myelogenous leukemia in accelerated phase. Haematologica (2007) 92(Suppl. 1):207-208 (Abstr. 0557).
15. OTTMANN O, LARSON R, KANTARJIAN H et al.: Nilotinib monotherapy in patients with imatinib-resistant or-intolerant Ph+ chronic myelogenous leukemia in blast crisis or relapsed/refractory Ph+ acute lymphoblastic leukemia. Haematologica (2007) 92(Suppl. 1):207 (Abstr. 0556).
16. JABBOUR E, CORTES J, O'BRIEN S, GILES F, KANTARJIAN H: New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance. Semin. Hematol. (2007) 44:25-31.
17. LEE FY, LOMBARDO L, CAMUSO A et al. : BMS-354825 potently inhibits multiple selected oncogenic tyrosine kinases and possesses broad-spectrum antitumor activities in vitro and in vivo. Proc. Am. Assoc. Cancer Res. (2005) 46:159 (Abstr. 675).
18. FABARIUS A, GIEHL M, KRAEMER A, et al. : Centrosome aberrations, disturbed mitotic spindle formation and G1 arrest in normal and leukemic cells treated with the SRC/ABL inhibitor dasatinib. Blood (2006) 108:614a-615a.
19. SONG L, MORRIS M, BAGUIT et al.: Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival. Cancer Res. (2006) 66:5542-5548.
20. O'HARE T, WALTERS DK, STOFFREGEN EP et al.: In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. (2005) 65:4500-4505.
21. TOKARSKIJS, NEWITT JA, CHANG CY et al. : The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. (2006) 66:5790-5797.
22. SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305:399-401.
23. BRISTOL-MYERS SQUIBB: Dasatinib (Sprycel) prescribing information (2007).
24. TALPAZ M, SHAH NP, KANTARJIAN H et al. : Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354:2531-2541.
25. HOCHHAUS A, KANTARJIAN HM, BACCARANI M et al. : Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood (2007) 109:2303-2309.
26. GUILHOT F, APPERLEY J, FACON T et al. : Dasatinib induces durable cytogenetic responses in patients with chronic-phase CML with resistance or intolerance to imatinib: updated results of the CA180013 (START-C) trial. Haematologica (2007) 92(Suppl. 1): 128 (Abstr. 0358).
27. GUILHOT F, APPERLEY J, KIM DW et al. : Dasatinib induces signifi cant hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in accelerated phase. Blood (2007) 109:4143-4150.
28. CORTES J, KIM DW, GUILHOT F et al.: Dasatinib (SPRYCEL) in patients (pts) with chronic myelogenous leukemia in accelerated phase (AP-CML) that is imatinib-resistant (im-r) or-intolerant (im-i): updated results of the CA180-005 START-A Phase II study. Blood (2006) 108:613a (Abstr. 2160).
29. CORTES J, ROUSSELOT P, KIM DW et al. : Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or-intolerant chronic myeloid leukemia in blast crisis. Blood (2007) 109:3207-3213.
30. MARTINELLI G, HOCHHAUS A, COUTRE S et al. : Dasatinib (SPRYCEL) effi cacy and safety in patients (pts) with chronic myelogenous leukemia in lymphoid (CML-LB) or myeloid blast (CML-MB) phase who are imatinib-resistant (im-r) or-intolerant (im-i). Blood (2006) 108:224a (Abstr. 745).
31. KANTARJIAN H, PASQUINI R, HAMERSCHLAK N et al. : Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized Phase II trial. Blood (2007) 109:5143-5150.
32. QUINTAS-CARDAMA A, KANTARJIAN H, O'BRIEN S et al.: Dasatinib is safe and effective in patients with previously untreated chronic myelogenous leukemia in chronic phase. Haematologica (2007) 92(Suppl. 1):129 (Abstr. 0360).
33. HOCHHAUS A, KIM DW, ROUSSELOT P et al. : Dasatinib dose and schedule optimization in chronic-phase CML resistant or intolerant to imatinib: results from a randomized Phase-III trial (CA180034). Haematologica (2007) 92(Suppl.1):128-129 (Abstr. 0359).
34. DOMBRET H, OTTMANN OG, GOH Y et al. : Dasatinib 140 mg QD vs 70 mg b.i.d. in advanced-phase CML or Ph(+) ALL resistant or intolerant to imatinib: results from a randomized, Phase-III trial (CA180035). Haematologica (2007) 92 (Suppl.1):319 (Abstr. 0859).
35. BERGERON A, RÉA D, LEVY V et al.: Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am. J. Respir. Crit. Care Med. (2007) 176:814-818.
36. CORTES J, TALPAZ M, O'BRIEN S et al. : Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin. Cancer Res. (2005) 11:3425-3432.
37. WANG L, PEARSON K, FERGUSON JE, CLARK RE: The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia. Br. J. Haematol. (2003) 120:990-999.
38. COPLAND M, HAMILTON A, ELRICK LJ et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 107:4532-4539.
39. MÜLLER MC, BRANFORD S, RADICH J et al.: Effi cacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR-ABL mutations. Haematologica (2007) 92(Suppl. 1):127 (Abstr. 0356).
40. SHAH NP: Dasatinib. Drugs Today (Barc) (2007) 43:5-12.